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Summary
Oncogenicmutations in the small Ras GTPases KRas, HRas,
and NRas render the proteins constitutively GTP bound
and active, a state that promotes cancer [1]. Ras proteins
share w85% amino acid identity [2], are activated by [3]
and signal through [4] the same proteins, and can exhibit
functional redundancy [5, 6]. Nevertheless, manipulating
expression or activation of each isoform yields different
cellular responses [7–10] and tumorigenic phenotypes
[11–13], even when different ras genes are expressed from
the same locus [6]. We now report a novel regulatory mech-
anism hardwired into the very sequence of RAS genes that
underlies how such similar proteins impact tumorigenesis
differently. Specifically, despite their high sequence simi-
larity, KRAS is poorly translated compared to HRAS due
to enrichment in genomically underrepresented or rare
codons. Converting rare to common codons increases
KRas expression and tumorigenicity to mirror that of HRas.
Furthermore, in a genome-wide survey, similar gene pairs
with opposing codon bias were identified that not only
manifest dichotomous protein expression but also are en-
riched in key signaling protein classes and pathways.
Thus, synonymous nucleotide differences affecting codon
usage account for differences between HRas and KRas
expression and function and may represent a broader regu-
lation strategy in cell signaling.
Results
Oncogenic HRAS cDNA, when ectopically overexpressed in
human cells, consistently produced 20-fold more protein
than the identically tagged oncogenic version of the major
splice form (4B) of KRAS cDNA (termed KRAS), regardless of
the method of introducing DNA, cell type, epitope tag,
promoter, exogenous UTRs, introns, mutations, or membrane
targeting (Figure 1A; see also Figures S1A–S1H available on-
line). To explore this difference further, we generated KRAS*
by fusing HRAS cDNA encoding the first 158 amino acids
(mutated at nine residues to match KRas) to KRAS cDNA en-
coding the terminal hypervariable 30 amino acids (Figure S1I).
KRAS* produced more KRas protein than KRAS, regardless of
other parameters, indicating that KRAS nucleotide sequence5These authors contributed equally to this work
*Correspondence: count004@mc.duke.edulimits protein expression. KRAS* still expressed less protein
than HRAS (Figures 1A, S1A–S1C, and S1E–S1G); whether
this is a consequence of the remaining KRAS sequence or is
due to other mechanisms remains to be determined. Addition-
ally, pERK and pAKT levels, measures of Ras effector activa-
tion, were similar in cells expressing oncogenic HRas, KRas,
or KRas* (Figure S1G). Brief metabolic labeling revealed higher
KRas protein expression from KRAS* compared to KRAS (Fig-
ure S1J), consistent with a translational etiology. Indeed,
glutathione S-transferase (GST) fused with KRAS cDNA
(GST-KRas) expressed little protein unless a STOP codon
was inserted between the two (GST-STOP-KRas) or KRas
protein was encoded from KRAS*, suggesting that ribosomes
stall upon entering KRAS mRNA (Figure 1B). Moreover, KRAS
and KRAS* mRNA levels were within 2-fold of HRAS mRNA
(Figure S1K), although KRAS was consistently the lowest,
perhaps reflecting no-go decay of stalled transcripts [14].
Thus, the nucleotide sequence of KRAS message impedes
translation.
Comparing the KRAS and HRAS sequence revealed that
the third position of codons was typically an A/T in KRAS but
G/C in HRAS. Based on human genome-wide analysis of the
relative frequencies that degenerate codons are used to
encode for the same amino acid [15], the A/T bias in KRAS
corresponds to underrepresented (rare) codons (Figure 1C).
Consistent with rare codons limiting protein expression,
KRas levels were increased when translated from KRAS*
mRNA (Figure 1A). Similarly, the bias toward rare codons
was conserved in mammalian and avian KRAS genes (Fig-
ure S1L) and equated with lower expression compared to
HRas in mammalian cells (Figure 1D). Moreover, zebrafish
hras and kras encoded by a mixture of rare and common
codons exhibited comparable protein expression at a level
between that of mammalian HRas and KRas (Figures 1D and
S1L). Finally, progressively converting rare to common codons
proportionally increased human KRas protein expression,
even upon changing only nine rare isoleucine and valine
codons scattered throughout KRAS to their common counter-
parts (Figures 1E and S1I). Thus, rare codons limit KRAS
translation.
To investigate this phenomenon at the endogenous level, we
infected HCT116 human cancer cells (which have a KRASG13D
allele) with an AAV targeting vector [16] designed to knock into
KRAS exon 1 either opKRASG13D (oncogenic KRASG13D cDNA
in which 130 rare codons were optimized to common codons)
or uaKRASG13D (unaltered KRASG13D cDNA). The resultant
transcripts would be expressed from the endogenous KRAS
promoter and retain the 50 UTR and first 17 coding nucleotides,
minimizing effects on translation initiation, but encode only
the KRAS4B spliced product (Figure 2A). Screening w1,800
neomycin-resistant clones revealed four with opKRASG13D
and two with uaKRASG13D cDNA successfully knocked into
one allele of the KRAS gene. Immunoblot revealed poor ex-
pression of endogenous KRas in both the uaKRASG13D and
control cell lines exhibiting a random integration event, on par
with the parental HCT116 cells. Conversely, the opKRASG13D
cell lines exhibited on average 5-fold higher KRas protein and
2-fold higher KRAS mRNA levels (Figures 2B, S2A, and S2B).
This increase was lower compared to the ectopic setting,
consistent with overexpression systemsmagnifying the effects
Figure 1. Translation of KRAS Is Limited by Rare
Codons
(A) Immunoblot of lysates isolated from human
HEK-HT cells stably infected with the retrovirus
pBABEpuro encoding the indicated N-terminal
FLAG epitope-tagged oncogenic (G12V) human
Ras proteins (FLAG-RasG12V) with an a-FLAG or
a-tubulin antibody. One of three experiments is
shown.
(B) Immunoblot of lysates isolated from HEK-HT
cells transiently transfected with the plasmid
pCIneo encoding GST cDNA, a STOP codon
where indicated, and in frame the indicated
FLAG-Ras cDNAs, with an a-GST or a-tubulin
antibody. One of three experiments is shown.
(C) Amino acid identity of HRas and KRas is
shown in the middle bar. Blue indicates identical
amino acids; white indicates nonidentical amino
acids. Relative codon usage of HRAS versus
KRAS is shown in the upper and lower bars,
respectively. Increasingly dark shades of red
indicate increasing relative rarity of the codon
for identical amino acids; gray indicates gaps in
alignment or nonidentical amino acids.
(D) Immunoblot of lysates isolated from human
HEK-HT cells stably infected with the retrovirus
pBABEpuro encoding the indicated FLAG-Ras
proteins isolated from the indicated species
with an a-FLAG or a-tubulin antibody. One of
two experiments is shown.
(E) Immunoblot of lysates isolated from
human HEK-HT cells stably infected with the
retrovirus pBABEpuro encoding FLAG-HRas,
FLAG-KRas, or FLAG-KRas* (in which the
indicated rare codons were progressively con-
verted to the indicated common codons) with an a-FLAG or a-tubulin antibody. One of two experiments is shown.
Detailed methodologies and reagent descriptions are provided in Supplemental Experimental Procedures. See also Figure S1.
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71of codon bias [17]. Thus, changing rare to common codons
increases endogenous KRas protein expression.
Polysome profiling was performed to characterize relative
ribosomal kinetics of endogenous HRAS and endogenous
untargeted KRAS mRNAs from HCT116 clone 5. Semiquanti-
tative RT-PCR revealed that both transcripts accumulated
in polysome fractions, although KRAS occupied relatively
heavier fractions despite nearly equal transcript length (Fig-
ure 2C), indicating more dense packing of ribosomes. Pacta-
mycin treatment to halt translation initiation (Figure S2C) led
to an accumulation of HRAS mRNA in lighter polysome and
ribosome-free fractions, indicative of ribosome translocation.
As observed previously [18], there was only a minimal shift of
KRAS mRNA in the gradient, with the bulk of the message
retained in the heavy fractions (Figure 2C). These results
were confirmed in HEK-HT cells (Figure S2D). Polysome
profiles of mRNA derived from the opKRASG13D HCT116 clone
5 and uaKRASG13D HCT116 clone 1 were compared. Quantita-
tive RT-PCR analysis revealed that after pactamycin treatment
(Figure S2C), opKRASG13D mRNA was modestly shifted to
lighter fractions relative to uaKRASG13D mRNA (Figure 2D),
consistent with the degree that other transcripts are shifted
upon alleviating ribosome stalling [19]. These shifts were reca-
pitulated in opKRASG13D HCT116 clone 4 (Figures S2C and
S2E). Thus, rare codons impede translation of endogenous
KRAS mRNA.
The biological impact of codon bias in mammalian genes is
largely unknown. However, targeted replacement of codons
in the Drosophila alcohol dehydrogenase gene with either
suboptimal [20] or optimal [21] codons can respectivelydecrease or increase enzyme activity and alcohol tolerance,
suggesting that codon bias affects gene function in higher
eukaryotes. Because oncogenic Ras can impart tumorigenic
growth to cells, we used tumor growth to assess the biological
impact of altering codon bias of human KRAS. HEK-HT
cells, which require oncogenic HRas for tumor growth [22],
were transduced with a vector expressing no transgene,
oncogenic HRasG12V, KRasG12V, or KRas*G12V (Figure 1A) and
assayed for tumor growth. KRasG12V, like vector cells, formed
tumors with 90-fold smaller masses and reduced kinetics
compared to HRasG12V cells, an effect rescued by KRAS*G12V
(Figures 3A–3C). Tumors that eventually formed 3 months
later from KRasG12V cells exhibited elevated KRas expres-
sion (Figure S3A). To examine the endogenous effect, we
compared opKRASG13D and uaKRASG13D knockin clones in
which targeted recombination occurred at the same wild-
type KRAS allele. opKRASG13D clone 5 formed tumors with
up to 30-fold larger masses and increased kinetics compared
to uaKRASG13D clones (Figures 3D–3F), although this was not
as dramatic as observed in the ectopic setting. Tumors from
opKRASG13D cells retained differential KRas protein expres-
sion and, interestingly, exhibited higher HRas expression
(data not shown). Although altering rare codons may affect
protein folding and processing [17], there is a direct correlation
among codon content, protein expression, and tumorigenesis
of ectopic and endogenous oncogenic KRAS.
To explore whether the differences in codon bias between
RAS genes reflect a broader regulation strategy, we performed
a genome-wide survey to identify gene pairs with high simi-
larity and divergent codon usage (Table S1) using G-C content
Figure 2. Rare Codon Bias Limits Endogenous KRAS Translation
(A) AAV-based recombination targeting strategy to knock into exon 1 of the
endogenous KRAS gene in human HCT116 colon cancer cells (ATCC) an
oncogenic KRASG13D cDNA in which either 130 rare codons were optimized
to common codons (opKRASG13D) or left unaltered (uaKRASG13D) [16].
(B) Immunoblot of lysates isolated from the parental HCT116 cell line, stable
clones with nonhomologous vector integration, clones with homologous
integration of uaKRASG13D, and clones with homologous integration of
opKRASG13D, with an a-KRas or a-tubulin antibody. Data shown are repre-
sentative of at least one experiment.
(C) Semiquantitative RT-PCR using primers specific for HRAS and the non-
targeted KRAS mRNA of the indicated sedimentation fractions (relative
positions of ribosome-free, ribosome subunits 40S, 60S, and 80S, and
polysome fractions) isolated from HCT116 opKRASG13D clone 5 pre (2)
and post (+) pactamycin (pacta) treatment to halt translation initiation.
(D) Quantitative RT-PCR using primers specific for the KRASG13D knockin
mRNA of the indicated sedimentation fractions isolated from HCT116
opKRASG13D clone 5 and uaKRASG13D clone 1 pre and post pactamycin
treatment to halt translation initiation.
Detailed methodologies and reagent descriptions are provided in Supple-
mental Experimental Procedures. See also Figure S2.
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Using KRAS and HRAS as a benchmark, the top 60 gene pairs
had R80% amino acid identity and R1.8-fold difference in
GC3 content (Figure 4A; Table S1). Twelve such cDNA pairs
were Myc epitope tagged and expressed in human cells. In
every case, the gene enriched in rare codons expressed less
protein. Changing rare to common codons in the two genes
CFL2 and ORMDL1 augmented protein expression to that of
CFL1 andORMDL3 (Figure 4B). Thus, synonymous differences
altering codon usage influence expression of mammalian
genes encoding similar proteins.
To assess the functional significance of this gene set, we
performed gene ontology analysis [23] on the top 150 gene
pairs sharing high identity and large differences in GC3
content (Table S1). Strikingly, we found that this set was
highly enriched for proteins with purine nucleotide binding
or kinase activity. This enrichment was six or more orders
of magnitude more significant than enrichment of any other
functional category from the analysis of gene pairs from
complementary combinations of identity and GC3 content
criteria (Figure 4C; Table S2). KEGG pathway analysis [24]
was also performed to determine whether gene pairs reside
in pathways. Insulin signaling, long-term potentiation, and
tight junction pathways, in particular, were significantly en-
riched for gene pairs with high protein identity and differential
codon usage (Figure 4D; Table S3). Thus, the combination of
two seemingly unrelated criteria—high protein identity and
opposing codon bias—identified unique functional classes
of proteins as well as signaling pathways.
Discussion
Although differences in KRas and HRas expression have
been previously reported in at least some settings [25],
the mechanism responsible and effects thereof remained
unknown. Here we present a novel regulatory strategy that
has been hiding in plain sight: codon bias. Rare codons
throughout KRAS message impede translation and corre-
spondingly protein, and to a lesser extent mRNA levels, and
reduce oncogenic activity. This was surprising because,
although rare codons impede protein translation in heterolo-
gous expression systems [26, 27] and common codon
bias exists in highly expressed genes in bacteria and yeast
[17], there are few reports of it affecting ectopic expres-
sion of homologous transcripts [28–30], let alone endoge-
nous mammalian genes. Moreover, codon bias in mammals
has been argued to be a by-product of genes residing
within larger genomic regions of nucleotide bias (isochores)
that affect chromatin functions like meiotic recombi-
nation [31]. Furthermore, in genome-wide translational
assessment, sites of ribosome stalling do not correlate with
presence of rare codons [32]. Nevertheless, the effects of
codon usage between RAS genes on protein expression
and function suggest that there are indeed consequences
resulting from synonymous differences at the nucleotide
level [20, 21, 33].
At face value, the finding that KRAS is an incredibly weak
oncogene due to rare codon bias seems at odds with this
gene being the most commonly mutated RAS isoform in
cancer [34]. However, untransformed cells are sensitive
to oncogenic stress [35], and increasing levels of trans-
genic HrasG12V result in progressively more growth-arrested
(senescent) cells and fewer mammary lesions in mice
[36]. Perhaps rare codons limit the expression of KRas to
Figure 3. Rare Codons Limit Oncogenic KRas-
Driven Tumorigenesis
(A–C) Photograph (A) and mean weight 6 SEM
(B) of tumors at endpoint, as well as mean
size 6 SEM of tumors over time (C) derived
from HEK-HT cells stably expressing empty
vector (black circles), HRasG12V (blue squares),
KRasG12V (red triangles), and KRas*G12V (green
triangles) (n = 4). One of two experiments is
shown. ***p < 0.001.
(D–F) Photograph (D) andmean weight6 SEM (E)
of tumors at endpoint, as well as mean size 6
SEM of tumors over time (F) derived from
HCT116 clones expressing opKRasG13D (clone
5; green triangles), uaKRasG13D (clone 1; red
squares), or uaKRasG13D (clone 2; black triangles)
(n = 6). One of two experiments is shown. ***p <
0.001.
(G) Change in IMR90 cell number over time
following acute expression of the indicated
FLAG-RasG12V constructs. Left: fold change in
crystal violet absorbance at 590 nm at the indi-
cated time points after cell plating is normalized
to day 1 for each cell line. Relative cell number
for IMR90 cells expressing any of the oncogenic
FLAG-Ras constructs was significantly lower
than empty vector control cells on days 8, 12,
and 18 (p < 0.01). Additionally, relative cell
numbers for both empty vector and FLAG-
KRASG12V-expressing cells were significantly
different from each other and FLAG-KRAS*G12V
and FLAG-HRASG12V cells on days 12 and 18
(p < 0.0001). Right: crystal violet staining of intact
cells at day 18, representative of four replicates.
Data shown are representative of at least one
experiment.
Detailed methodologies and reagent descrip-
tions are provided in Supplemental Experimental
Procedures. See also Figure S3.
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73an ideal range to initiate tumorigenesis—high enough to pro-
mote hyperplasia but low enough to avoid excessive senes-
cence. Indeed, IMR90 primary human fibroblasts expressing
KRAS*G12V orHRASG12V, but notKRASG12V, appeared to arrest
with a senescent morphology (Figure 3G; data not shown).
Interestingly, there is concordance between the degree of
rare codon bias and the mutation frequency among RAS
family members (Figures S3B and S3C). However, codon
bias cannot alone account for this difference, because Hras
cDNA knocked into the Kras locus is mutated at a high
frequency in a urethane model of lung cancer [6]. Neverthe-
less, rare codons clearly crippled the oncogenic activity of
KRAS, which could be a barrier to malignant progression. In
this regard, it has been hypothesized that upregulation of
oncogenic KRas is a necessary intermediate step in tumor pro-
gression after senescence escape [36]. Multiple mechanismsthat may increase KRas expression
occur during cancer, including KRAS
gene amplification [37, 38], microRNA
downregulation directly [39, 40] or
indirectly by sequestration via KRAS
pseudogene mRNA [41], and a general
increase in tRNA levels [42, 43].
It was also striking that the divergent
tumorigenesis phenotypes of two nearly
identical proteins were reconciled by
altering codon usage. It is formallypossible that changing codon bias affected some other aspect
of mRNA regulation, but the multitude of complementary
codon modification strategies implemented make this
possibility less likely. Codon usage might underlie functional
differences between members in other protein families
with opposing codon bias. The enrichment of gene pairs
with high amino acid sequence identity and divergent
codon bias in signaling networks further suggests that
codon usage may impact entire signaling pathways. Indeed,
differential regulation of functionally redundant genes may
add specificity to signal transduction [44], and there are
situations in which transcripts enriched in rare codons are
preferentially translated in mammalian cells [45]. Thus, codon
bias is not only a novel mechanism regulating Ras isoforms
but may reflect a broader regulatory strategy in signaling
pathways.
Figure 4. Gene Pairs with Divergent Codon Bias
Demonstrate Correlating Differences in Expres-
sion and Cluster in Unique Signaling Protein
Classes
(A) Percent amino acid identity versus log differ-
ence in CDS GC3 content of individual protein
pairs identified by BLAST alignment (gray points).
Black points: gene pairs with R80% identity
and R1.8-fold difference in GC3 content; blue
crosses: gene pairs tested for protein expres-
sion; red cross: HRAS-KRAS gene pair.
(B) Immunoblot of lysates isolated from human
293 cells (ATCC) stably infected with the retro-
virus pBABEpuro encoding the indicated
N-terminal FLAG epitope-tagged cDNAs corre-
sponding to human gene pairs of high amino
acid sequence identity that have a common (first)
versus a rare (second) codon bias, or the gene
pair enriched in rare codons after rare codons
were optimized (op) to common codons, with
an a-FLAG or a-tubulin antibody. Data shown
are representative of at least one experiment.
(C and D) Histogram comparing p values of gene
ontology categories (C) or KEGG signaling
pathways (D) enriched in lists of gene pairs with
high amino acid sequence identity and high
GC3 difference (green), high identity and low
GC3 difference (pink), low identity and high GC3
difference (purple), or lists of genes with high
GC3 content (brown) or low GC3 content (aqua-
marine).
Detailed methodologies and reagent descrip-
tions are provided in Supplemental Experimental
Procedures. See also Tables S1, S2, and S3.
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